Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Dosing of…
read more
20 Aug 2020
0

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Closing of…
read more
20 Aug 2020
0

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Pricing of…
read more
20 Aug 2020
0

Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

Post by: Geert in Fund+ Press Release
Fund+ Establishes ExeVir Bio with…
read more
28 Jul 2020
0

Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV

Post by: Geert in Fund+ Press Release
Fund+ Leads EUR38 Million Series…
read more
27 Jul 2020
0

Aelin Therapeutics awarded €2.3 million VLAIO research grant

Post by: Geert in Aelin Therapeutics Press Release
Aelin Therapeutics awarded €2.3 million…
read more
13 Jul 2020
0

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

Post by: Geert in eTheRNA Press Release
eTheRNA raises EUR 34 million…
read more
16 Jun 2020
0

Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing

Post by: Geert in Fund+ Press Release
Fund+ Announces Investment in Ona…
read more
16 Jun 2020
0

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces First Patients…
read more
15 Jun 2020
0

Notable Board Changes

Post by: Geert in Fund+ Press Release
Notable Board Changes Fund+ Appoints…
read more
15 Jun 2020
0